UBS AM’s Celularity CELU Stock Holding History

UBS AM’s Portfolio CELU Stock Details CELU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-2,913	Closed	-$37.6K	–	2685
2022 Q4	$37.6K	Hold	2,913	–	–	﹤0.01%	2513
2022 Q3	$67.3K	Hold	2,913	–	–	﹤0.01%	2709
2022 Q2	$99.1K	Buy	+2,913	New	+$237K	﹤0.01%	2650

Other funds holding CELU

SIC

Starr International Company Zug, Switzerland $19.9M AUM 39.69% 1-Year Est. Return

CVSC

C.V. Starr & Co New York $187M AUM 26.03% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

BFO

Biltmore Family Office Charlotte, North Carolina $761M AUM 31.91% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

UBS AM's CELU Position: Q1 2023 in Review

UBS AM sold out of Celularity (CELU) in Q1 2023, closing a stake of 2,913 shares — an estimated $37.6K sold.

UBS AM first reported a position in CELU in Q2 2022 and held it in 3 quarters. The position peaked at $99.1K in Q2 2022. 61 funds tracked by Wall St. Rank hold CELU as of Q1 2023.

UBS AM reported no remaining Celularity position as of Q1 2023 after selling out during the quarter.
UBS AM sold 2,913 Celularity shares in Q1 2023, an estimated $37.6K.
UBS AM first reported a position in Celularity in Q2 2022 and held it in 3 quarters.
UBS AM's Celularity position peaked at $99.1K in Q2 2022.
61 funds tracked by Wall St. Rank held Celularity as of Q1 2023.

Based on UBS AM's 13F filing for Q1 2023, filed 15 May 2023.